Clinical Effects of Use Polymyxin B Fixed on Fibers in Liver Transplant Patients With Severe Sepsis or Septic Shock

Ruberto, Franco; Pugliese, Francesco; DaLio, Andrew L.; Martelli, S.; Bruno, Katelyn A.; Marcellino, V.; Perrella, S.; Cappannoli, A.; Mazzarino, V.; Tosi, Antonella; Novelli, G.; Rossi, Massimo; Corradini, Stefano Ginanni; Ferretti, G.; Berloco, P.; Pietropaoli, P

doi:10.1016/j.transproceed.2007.05.064

Cited by 8 publications

(6 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…(42). Similar phenomena have been demonstrated for cationic antibiotics (e.g., polymyxin B) that bind to the lipid A portion of lipopolysaccharides in gram-negative bacteria (30).…”

supporting

confidence: 62%

Silver as a Residual Disinfectant To Prevent Biofilm Formation in Water Distribution Systems

Silvestry-Rodriguez

Bright

Slack

et al. 2008

Appl Environ Microbiol

View full text Add to dashboard Cite

show abstract

“…(42). Similar phenomena have been demonstrated for cationic antibiotics (e.g., polymyxin B) that bind to the lipid A portion of lipopolysaccharides in gram-negative bacteria (30).…”

supporting

confidence: 62%

Silver as a Residual Disinfectant To Prevent Biofilm Formation in Water Distribution Systems

Silvestry-Rodriguez

Bright

Slack

et al. 2008

Appl Environ Microbiol

View full text Add to dashboard Cite

show abstract

“…Therefore, our data suggest that galectin-3 may suppress LPS function by interacting with LPS via lipid A and/or ␤-lactose motifs using N-terminal nonlectin and/or C-terminal lectin domain, respectively. Polymyxin B neutralizes LPS activity by binding to the lipid A domain, which also blocks the interaction between LPS and galectin-3 (25,29). Preincubation of LPS and lipid A with polymyxin B almost completely abolished their effect on galectin-3…”

Section: Galectin-3 Binds To Lps and Blocks Lps-induced Inflammatory mentioning

confidence: 99%

Galectin-3 Is a Negative Regulator of Lipopolysaccharide-Mediated Inflammation

Komai-Koma

Gilchrist

et al. 2008

The Journal of Immunology

143

114

View full text Add to dashboard Cite

Galectin-3 is a β-galactoside-binding lectin that plays an important role in inflammatory diseases. It also interacts with the surface carbohydrates of many pathogens, including LPS. However, its role in infection is not fully understood. Data presented herein demonstrate for the first time that galectin-3 is a negative regulator of LPS-induced inflammation. Galectin-3 is constitutively produced by macrophages and directly binds to LPS. Galectin-3-deficient macrophages had markedly elevated LPS-induced signaling and inflammatory cytokine production compared with wild-type cells, which was specifically inhibited by the addition of recombinant galectin-3 protein. In contrast, blocking galectin-3 binding sites by using a neutralizing Ab or its ligand, β-lactose, enhanced LPS-induced inflammatory cytokine expression by wild-type macrophages. In vivo, mice lacking galectin-3 were more susceptible to LPS shock associated with excessive induction of inflammatory cytokines and NO production. However, these changes conferred greater resistance to Salmonella infection. Thus, galectin-3 is a previously unrecognized, naturally occurring, negative regulator of LPS function, which protects the host from endotoxin shock but, conversely, favors Salmonella survival.

show abstract

“…Although the mechanisms are currently under investigation, it has been reported that PMX‐DHP for septic shock is clinically safe and effective (24–26). Although PMX‐DHP improves hemodynamic status and cardiac function in LT patients with severe sepsis or septic shock due to Gram‐negative bacteria, its major beneficial effect in pediatric recipients may be improvement of respiratory dysfunction (9–11). In our present series of pediatric patients, the use of PMX‐DHP was shown to be safe and effective.…”

Section: Discussionmentioning

confidence: 57%

“…Nafamostat mesilate (Torii Pharmaceuticals, Tokyo, Japan) or heparin sodium (Mochida Pharmaceuticals, Tokyo, Japan) were used. Our protocol and indication for apheresis and dialysis for each disease shown in Table 1 based on previous reports (1–12).…”

Section: Methodsmentioning

confidence: 99%

“…In the field of LT, the indications for apheresis and dialysis are classified as renal indications and non‐renal indications. The potential roles of apheresis and dialysis may include (1–12): (i) renal replacement therapy for ARF; (ii) bridging therapy until LT for acute liver failure (ALF); (iii) treatment of hyperammonemia due to congenital metabolic diseases; (iv) treatment of liver allograft dysfunction (primary allograft dysfunction with hyperbilirubinemia) after LT; (v) endotoxin or cytokine removal for sepsis associated with multi‐organ failure; (vi) antibody removal for patients undergoing ABO blood type‐incompatible LT; and (vii) fluid management for acute respiratory failure due to fluid overload.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Role of Apheresis and Dialysis in Pediatric Living Donor Liver Transplantation: A Single Center Retrospective Study

Sanada¹,

Mizuta²,

Urahashi³

et al. 2012

Ther Apher Dial

View full text Add to dashboard Cite

In the field of pediatric living donor liver transplantation, the indications for apheresis and dialysis, and its efficacy and safety are still a matter of debate. In this study, we performed a retrospective investigation of these aspects, and considered its roles. Between January 2008 and December 2010, 73 living donor liver transplantations were performed in our department. Twenty seven courses of apheresis and dialysis were performed for 19 of those patients (19/73; 26.0%). The indications were ABO incompatible-liver transplantation in 11 courses, fluid management in seven, acute liver failure in three, renal replacement therapy in two, endotoxin removal in two, cytokine removal in one, and liver allograft dysfunction in one. Sixteen courses of apheresis and dialysis were performed prior to liver transplantation for 14 patients. The median IgM antibody titers before and after apheresis for ABO blood type-incompatible liver transplantation was 128 and eight, respectively (P < 0.05). Eleven courses of apheresis and dialysis were performed post liver transplantation for 10 patients. The median PaO2/FiO2 ratio before and after dialysis for fluid overload was 159 and 339, respectively (P < 0.05). No bleeding or technical complications attributable to apheresis and dialysis occurred. The 1-year survival rate of the patients was 100%. Apheresis and dialysis in pediatric living donor liver transplantation are effective for antibody removal in ABO-incompatible liver transplantation, and fluid management for acute respiratory failure.

show abstract

Clinical Effects of Use Polymyxin B Fixed on Fibers in Liver Transplant Patients With Severe Sepsis or Septic Shock

Cited by 8 publications

References 9 publications

Silver as a Residual Disinfectant To Prevent Biofilm Formation in Water Distribution Systems

Silver as a Residual Disinfectant To Prevent Biofilm Formation in Water Distribution Systems

Galectin-3 Is a Negative Regulator of Lipopolysaccharide-Mediated Inflammation

Role of Apheresis and Dialysis in Pediatric Living Donor Liver Transplantation: A Single Center Retrospective Study

Contact Info

Product

Resources

About